The need for a shared definition of the atopic dermatitis ‘super responder’ in the ‘treat-to-target’ era
In the last few years, the introduction of monoclonal antibody and Janus kinase inhibitors in the treatment of atopic dermatitis has revolutionized and elevated the therapeutic targets of this disease. Recently, several proposals for treat-to-target strategies have been published, the most important of which converge on achieving specific clinical and quality-of-life outcomes.
Authors
- Luca Mastorino (ORCID: https://orcid.org/0000-0001-7386-3219)
- Simone Ribero (ORCID: https://orcid.org/0000-0002-0098-1406)
- Michela Ortoncelli (ORCID: https://orcid.org/0009-0002-6774-7080)
- Pedro Mendes‐Bastos (ORCID: https://orcid.org/0000-0002-2439-920X)
Institutions
- Hospital do Desterro (PT)
- University of Turin (IT)
Publication Details
- Journal
- Clinical and Experimental Dermatology
- Published
- 2024-12-13
- DOI
- https://doi.org/10.1093/ced/llae542
- Citations
- 1
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.53